BlackRock’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $59.5M | Sell |
2,967,134
-30,995
| -1% | -$622K | ﹤0.01% | 2319 |
|
|
2025
Q1 | $59M | Buy |
2,998,129
+33,001
| +1% | +$649K | ﹤0.01% | 2270 |
|
|
2024
Q4 | $66.7M | Buy |
2,965,128
+28,486
| +1% | +$641K | ﹤0.01% | 2264 |
|
|
2024
Q3 | $75M | Buy |
2,936,642
+205,869
| +8% | +$5.26M | ﹤0.01% | 2215 |
|
|
2024
Q2 | $63.8M | Buy |
2,730,773
+917,422
| +51% | +$21.4M | ﹤0.01% | 2250 |
|
|
2024
Q1 | $31.9M | Sell |
1,813,351
-36,307
| -2% | -$639K | ﹤0.01% | 2669 |
|
|
2023
Q4 | $25.6M | Buy |
1,849,658
+282,126
| +18% | +$3.9M | ﹤0.01% | 2813 |
|
|
2023
Q3 | $21.4M | Buy |
1,567,532
+21,057
| +1% | +$288K | ﹤0.01% | 2858 |
|
|
2023
Q2 | $31.6M | Buy |
1,546,475
+1,512,680
| +4,476% | +$30.9M | ﹤0.01% | 2700 |
|
|
2023
Q1 | $740K | Buy |
33,795
+5,157
| +18% | +$113K | ﹤0.01% | 4350 |
|
|
2022
Q4 | $469K | Buy |
28,638
+1,189
| +4% | +$19.5K | ﹤0.01% | 4538 |
|
|
2022
Q3 | $252K | Sell |
27,449
-3,291
| -11% | -$30.2K | ﹤0.01% | 4827 |
|
|
2022
Q2 | $150K | Buy |
30,740
+3,891
| +14% | +$19K | ﹤0.01% | 5022 |
|
|
2022
Q1 | $202K | Buy |
26,849
+900
| +3% | +$6.77K | ﹤0.01% | 5015 |
|
|
2021
Q4 | $234K | Buy |
25,949
+175
| +0.7% | +$1.58K | ﹤0.01% | 5002 |
|
|
2021
Q3 | $420K | Buy |
25,774
+6,355
| +33% | +$104K | ﹤0.01% | 4739 |
|
|
2021
Q2 | $613K | Sell |
19,419
-94,673
| -83% | -$2.99M | ﹤0.01% | 4575 |
|
|
2021
Q1 | $3.85M | Buy |
114,092
+3,134
| +3% | +$106K | ﹤0.01% | 3996 |
|
|
2020
Q4 | $9.79M | Buy |
110,958
+26,260
| +31% | +$2.32M | ﹤0.01% | 3305 |
|
|
2020
Q3 | $6.89M | Sell |
84,698
-1,039
| -1% | -$84.5K | ﹤0.01% | 3342 |
|
|
2020
Q2 | $9.48M | Buy |
+85,737
| New | +$9.48M | ﹤0.01% | 3148 |
|